How Marco Pharma International Preserves German Homeopathic Traditions in America 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Zug, Switzerland, Dec. 28, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will provide an update on its development program with AM-111 for the treatment of acute inner ear hearing loss on Thursday, January 4, 2018. Following the announcement, Auris Medical's management team will host a live conference call and webcast at 8:00 am Eastern Time (2:00 pm Central European Time), featuring Hinrich Staecker, MD, PhD, Professor of Otolaryngology at the University of Kansas Medical Center. Dr Staecker trained at Albert Einstein College of Medicine and Massachusetts Eye and Ear infirmary and has been in practice for over 25 years with a primary focus on neurotology and otology. His research activities are mainly dedicated to developing treatments for hearing loss. Dr. Staecker has published numerous articles and book chapters.
To participate in this conference call, dial 1-800-281-7973 (USA) or +1-646-828-8156 (International), and enter passcode 2284504. A live webcast of the conference call can be accessed in the Investor Relations section of the Auris Medical website at www.aurismedical.com. A replay will be available approximately two hours following the live call.
About Auris Medical
Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in neurotology. The company is focused on the Phase 3 development of treatments for acute inner ear hearing loss (AM-111) and for acute inner ear tinnitus (Keyzilen®; AM-101) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is developing intranasal betahistine for the treatment of vertigo (AM-125) as well as early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of Auris Medical Holding AG trade on the NASDAQ Capital Market under the symbol "EARS."
Investor contact: Daniel Ferry, LifeSci Advisors, 1-617-535-7746, [email protected]
